Literature DB >> 19098294

Effect of tunicamycin on Candida albicans biofilm formation and maintenance.

Christopher G Pierce1, Derek P Thomas, José L López-Ribot.   

Abstract

BACKGROUND: Candida albicans is a common opportunistic pathogen of the human body and is the frequent causative agent of candidiasis. Typically, these infections are associated with the formation of biofilms on both host tissues and implanted biomaterials. As a result of the intrinsic resistance of C. albicans biofilms to most antifungal agents, new strategies are needed to combat these infections.
METHODS: Here we have used a 96-well microtitre plate model of C. albicans biofilm formation to study the inhibitory effect of tunicamycin, a nucleoside antibiotic that inhibits N-linked glycosylation affecting cell wall and secreted proteins, on C. albicans biofilm formation. A proteomic approach was used to study the effect of tunicamycin on levels of glycosylation of key secreted mannoproteins in the biofilm matrix.
RESULTS: Our results revealed that physiological concentrations of tunicamycin displayed significant inhibitory effects on biofilm development and maintenance, while not affecting overall cell growth or morphology. However, tunicamycin exerted a minimal effect on fully mature, pre-formed C. albicans biofilms.
CONCLUSIONS: The effect of tunicamycin on the C. albicans biofilm mode of growth demonstrates the importance of N-linked glycosylation in the developmental stages of biofilm formation. In addition, our results indicate that N-linked glycosylation represents an attractive target for the development of alternative strategies for the prevention of biofilm formation by this important pathogenic fungus.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19098294      PMCID: PMC2721703          DOI: 10.1093/jac/dkn515

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  37 in total

1.  Microbial biofilms: e pluribus unum.

Authors:  Clarissa J Nobile; Aaron P Mitchell
Journal:  Curr Biol       Date:  2007-05-15       Impact factor: 10.834

Review 2.  Cell wall and secreted proteins of Candida albicans: identification, function, and expression.

Authors:  W L Chaffin; J L López-Ribot; M Casanova; D Gozalbo; J P Martínez
Journal:  Microbiol Mol Biol Rev       Date:  1998-03       Impact factor: 11.056

3.  Tunicamycin--an inhibitor of yeast glycoprotein synthesis.

Authors:  S C Kuo; J O Lampen
Journal:  Biochem Biophys Res Commun       Date:  1974-05-07       Impact factor: 3.575

4.  Role of dimorphism in the development of Candida albicans biofilms.

Authors:  George S Baillie; L Julia Douglas
Journal:  J Med Microbiol       Date:  1999-07       Impact factor: 2.472

Review 5.  Molecular organization of the cell wall of Candida albicans and its relation to pathogenicity.

Authors:  José Ruiz-Herrera; M Victoria Elorza; Eulogio Valentín; Rafael Sentandreu
Journal:  FEMS Yeast Res       Date:  2006-01       Impact factor: 2.796

6.  Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance.

Authors:  J Chandra; D M Kuhn; P K Mukherjee; L L Hoyer; T McCormick; M A Ghannoum
Journal:  J Bacteriol       Date:  2001-09       Impact factor: 3.490

Review 7.  Genetics and genomics of Candida albicans biofilm formation.

Authors:  Clarissa J Nobile; Aaron P Mitchell
Journal:  Cell Microbiol       Date:  2006-07-11       Impact factor: 3.715

Review 8.  Candida infections of medical devices.

Authors:  Erna M Kojic; Rabih O Darouiche
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

9.  Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System.

Authors:  C Beck-Sagué; W R Jarvis
Journal:  J Infect Dis       Date:  1993-05       Impact factor: 5.226

10.  A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients.

Authors:  Peter G Pappas; John H Rex; Jeannette Lee; Richard J Hamill; Robert A Larsen; William Powderly; Carol A Kauffman; Newton Hyslop; Julie E Mangino; Stanley Chapman; Harold W Horowitz; John E Edwards; William E Dismukes
Journal:  Clin Infect Dis       Date:  2003-08-14       Impact factor: 9.079

View more
  16 in total

Review 1.  Proteomics dedicated to biofilmology: What have we learned from a decade of research?

Authors:  Arbia Khemiri; Thierry Jouenne; Pascal Cosette
Journal:  Med Microbiol Immunol       Date:  2015-06-12       Impact factor: 3.402

2.  A haploid genetic screen identifies the major facilitator domain containing 2A (MFSD2A) transporter as a key mediator in the response to tunicamycin.

Authors:  Jan H Reiling; Clary B Clish; Jan E Carette; Malini Varadarajan; Thijn R Brummelkamp; David M Sabatini
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-15       Impact factor: 11.205

3.  In vitro analysis of finasteride activity against Candida albicans urinary biofilm formation and filamentation.

Authors:  Alba A Chavez-Dozal; Livia Lown; Maximillian Jahng; Carla J Walraven; Samuel A Lee
Journal:  Antimicrob Agents Chemother       Date:  2014-07-21       Impact factor: 5.191

4.  Community participation in biofilm matrix assembly and function.

Authors:  Kaitlin F Mitchell; Robert Zarnowski; Hiram Sanchez; Jessica A Edward; Emily L Reinicke; Jeniel E Nett; Aaron P Mitchell; David R Andes
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-13       Impact factor: 11.205

Review 5.  Filamentous fungal biofilms: Conserved and unique aspects of extracellular matrix composition, mechanisms of drug resistance and regulatory networks in Aspergillus fumigatus.

Authors:  Shuai Liu; Francois Le Mauff; Donald C Sheppard; Shizhu Zhang
Journal:  NPJ Biofilms Microbiomes       Date:  2022-10-19       Impact factor: 8.462

6.  High-throughput screening of a collection of known pharmacologically active small compounds for identification of Candida albicans biofilm inhibitors.

Authors:  Samuel A Siles; Anand Srinivasan; Christopher G Pierce; José L Lopez-Ribot; Anand K Ramasubramanian
Journal:  Antimicrob Agents Chemother       Date:  2013-05-20       Impact factor: 5.191

7.  Cyclooxygenase inhibitors reduce biofilm formation and yeast-hypha conversion of fluconazole resistant Candida albicans.

Authors:  E Abdelmegeed; Mona Ibrahim Shaaban
Journal:  J Microbiol       Date:  2013-09-14       Impact factor: 3.422

8.  Evaluation of Anti-Biofilm Capability of Cordycepin Against Candida albicans.

Authors:  Yu Wang; Zejun Pei; Zaixiang Lou; Hongxin Wang
Journal:  Infect Drug Resist       Date:  2021-02-05       Impact factor: 4.003

9.  The MP65 gene is required for cell wall integrity, adherence to epithelial cells and biofilm formation in Candida albicans.

Authors:  Silvia Sandini; Annarita Stringaro; Silvia Arancia; Marisa Colone; Francesca Mondello; Susanna Murtas; Antonietta Girolamo; Nicolina Mastrangelo; Flavia De Bernardis
Journal:  BMC Microbiol       Date:  2011-05-16       Impact factor: 3.605

10.  Candida albicans isolates from the gut of critically ill patients respond to phosphate limitation by expressing filaments and a lethal phenotype.

Authors:  Kathleen Romanowski; Alexander Zaborin; Vesta Valuckaite; Ronda J Rolfes; Trissa Babrowski; Cindy Bethel; Andrea Olivas; Olga Zaborina; John C Alverdy
Journal:  PLoS One       Date:  2012-01-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.